Hot Biotech Bullish Stocks: Genocea Biosciences (NASDAQ:GNCA), Esperion Therapeutics (NASDAQ:ESPR), Anacor Pharmaceuticals (NASDAQ:ANAC), CEL-SCI (NYSEMKT:CVM)

Technology Stocks News 16

Vaccine specialist Genocea Biosciences Inc (NASDAQ:GNCA) struck a research deal with Dana-Farber Cancer Institute and Harvard Medical School to study cancer immunology. Under the March 5 alliance, researchers will use Genocea Biosciences Inc (NASDAQ:GNCA)’s proprietary T cell antigen discovery platform to find antigens that correlate with an anti-tumor immune response in melanoma patients. Genocea Biosciences Inc (NASDAQ:GNCA) stock performance was 23.28% in last session and finished the day at $22.45. Traded volume was 131.58K shares in the last session and the average volume of the stock remained 179.51K shares.

ETC-1002, a novel agent in development by Esperion Therapeutics Inc (NASDAQ:ESPR), lowered LDL levels by nearly 43% in patients with type 2 diabetes and hypercholesterolemia, according to phase 2 study results. Esperion Therapeutics Inc (NASDAQ:ESPR) rose 5.58 percent to $17.40 Friday on volume of 160,479.00million shares. The intra-day range of the stock was $16.37 to $17.74. Esperion Therapeutics Inc (NASDAQ:ESPR) has a market capitalization of $267.22million.

Anacor Pharmaceuticals Inc (NASDAQ:ANAC) CEO David Perry sold 65,000 shares of the company’s stock in a transaction dated Wednesday, March 5th. Anacor Pharmaceuticals Inc (NASDAQ:ANAC)’s stock on Mar 7, 2014 reported a increase of 6.01% to the closing price of $21.16. Its fifty two weeks range is $3.50-$23.04. The total market capitalization recorded $862.18million. The overall volume in the last trading session was 481,323.00million shares. In its share capital, ANA has 40.59million outstanding shares.

Drug maker CEL-SCI Corporation (NYSEMKT:CVM) announced that its first U.S located clinical trial site has been commissioned to conduct its phase 3 tests on its cancer drug injection “Multikine* (Leukocyte Interleukin) which is designed to treat head and neck cancer. On Friday, shares of CEL-SCI Corporation (NYSEMKT:CVM) advanced 11.90% to close the day at $1.41. Company return on investment (ROI) is -253.80% and its monthly performance is recorded as 48.42%. CEL-SCI Corporation (NYSEMKT:CVM) quarterly revenue growth is 78.48%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone